In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on PolyPid (PYPD – Research Report), with a price target of $16.00. The company’s shares closed last Wednesday at $5.32.
According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of -17.0% and a 24.4% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma.
PolyPid has an analyst consensus of Strong Buy, with a price target consensus of $21.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on PolyPid’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.87 million. In comparison, last year the company had a GAAP net loss of $8.69 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company’s proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
Read More on PYPD: